Search Results

You are looking at 1 - 10 of 93 items for :

  • "dose intensity" x
  • User-accessible content x
Clear All
Full access

Gary H. Lyman

2006 ; 106 : 2258 – 2266 . 3 Lyman GH Dale DC Crawford J . Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices . J Clin Oncol 2003 ; 21 : 4524 – 4531 . 4

Full access

Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M. Favret, Phuong Khanh Morrow, Richard L. Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia and Gary H. Lyman

to improve patient outcomes. 22 Relative dose intensity (RDI), or the ratio of delivered dose intensity to standard or planned dose intensity, is a summary measure that is commonly used to describe dose delays and/or reductions that occur within a

Full access

David C. Dale, Gordon C. McCarter, Jeffrey Crawford and Gary H. Lyman

results of 20 years of follow-up . N Engl J Med 1995 ; 332 : 901 – 906 . 2 Wood WC Budman DR Korzun AH . Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma . N Engl J Med 1994 ; 330 : 1253

Full access

Gary H. Lyman

Crawford J Dale DC Lyman GH . Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management . Cancer 2004 ; 100 : 228 – 237 . 7 Dale DC McCarter GC Crawford J . Myelotoxicity and dose intensity of chemotherapy

Full access

Gary H. Lyman and David C. Dale

complications, including febrile neutropenia, infection, and infection-related mortality, in patients undergoing cancer chemotherapy, while enabling an increase in delivered chemotherapy dose intensity. 1 , 2 Clinical practice guidelines from NCCN, ASCO, and

Full access

Ashley E. Glode, S. Lindsey Davis, Supriya K. Jain, Megan D. Marsh, Lisa J. Wingrove, Tracey E. Schefter, Karyn Goodman, Lindel C.K. Dewberry, Martin D. McCarter, Laura Melton, Michelle Bunch, William T. Purcell and Stephen Leong

STRENGTH pathway, a retrospective QI analysis assessed an equal number of patients in the pre-STRENGTH and STRENGTH group for chemotherapy and radiation therapy dose intensities, as well as treatment outcomes. Results: During the pre-STRENGTH period

Full access

Rodger J. Winn

References 1. Phillips LS Branch WT Cook CB . Clinical inertia . Ann Int Med 2001 ; 135 : 825 – 834 . 2. Shayne M Crawford J Dale DC . Predictors of reduced dose intensity in patients with early-stage breast cancer

Full access

Jeffrey Crawford, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff and Gary H. Lyman

. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer 2006 ; 106 : 2258 – 2266 . 3. Hryniuk W Bush H . The importance of dose intensity in chemotherapy of metastatic breast cancer . J Clin Oncol

Full access

Robert E. Smith Jr.

://www.nccn.org . Accessed May 23, 2006 . 4. Kim ES Vokes EE Kies MS . Cetuximab in cancers of the lung and head & neck . Semin Oncol 2004 ; 31 ( suppl 1 ): 61 – 67 . 5. Hryniuk W Levine MN . Analysis of dose intensity for adjuvant chemotherapy

Full access

Gary H. Lyman and Marek S. Poniewierski

, facilitating the safe delivery of planned chemotherapy dose intensity on schedule. Guidelines from NCCN and ASCO on the use of MGFs have recently been updated. 7 , 8 When selecting patients for primary prophylaxis with G-CSF, current guidelines recognize the